Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Gyre Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
For fiscal 2013 it was $1.14M, down 42.8% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $1.14M | -42.8% |
| FY2012 | Dec 31, 2012 | $1.99M | -38.4% |
| FY2011 | Dec 31, 2011 | $3.23M | +5.5% |
| FY2010 | Dec 31, 2010 | $3.06M | – |
See a number that looks wrong?